About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)

By: via ACN Newswire
TOKYO, Jan 13, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Taiwanese subsidiary Eisai Taiwan Inc. and Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. have launched "CogMateTM", a digital tool (non-medical device) for self-assessment of brain performance (brain health). In Taiwan and Hong Kong, the both subsidiaries target corporate customers such as municipalities and corporations in the sales. This will be the first release of "CogMate" in the Asian region (excluding Japan). In the near future, "CogMate" will be launched in countries such as Singapore.

"CogMate" is a multilingual overseas model of "NouKNOW" (product name in Japan), a digital tool (non-medical device) for self-assessment of brain performance, developed and distributed by Eisai using the cognitive function test "Cogstate Brief BatteryTM" (CBB) created by Cogstate, Ltd. (Headquarters: Australia). For the Asian region, "CogMate" is equipped with multilingual functions such as Chinese (Traditional Chinese) and English.

"CogMate" is conducted through a simple card test using a PC, tablet device or smartphone to quantitatively measure brain performance in four checking items evaluating psychomotor function, attention, learning and memory, and working memory. Users can self-assess and in a short time frame (approx. 15 minutes), enabling regular assessments in instances such as daily life and health checkups. On the screen showing the measurement results, a score (brain performance index (BPI)) - as a measurement of quantified brain performance aspects such as memorization, cognition, and decision - appears along with lifestyle advice for maintaining brain performance.

In Asia, with the rapid aging of the population in recent years, the total number of those living with dementia across the region is expected to increase year by year. With regard to dementia, in addition to medical expenses, the burden on the family and the social burden are heavy, which has become a social issue.

With the launch of "CogMate", Eisai will promote self-check and prevention activities for the maintenance and improvement of brain performance toward constructing an ecosystem to realize supporting people living with and preventing dementia in Asia. Eisai will continue to focus on delivering solutions to The People, including not only those living with dementia but also society at large, to remove the anxiety associated with dementia.

About "CogMate" / "NouKNOW" (pronounced "NOH-NOH")

Eisai holds the rights for exclusive development and commercialization worldwide, both medical and non-medical, for all cognitive function tests including "Cogstate Brief Battery" (CBB) created by Cogstate, Ltd. ("Cogstate"). CBB is a digital tool with abundant usage record and high evidence, which enables self-assess of cognitive function. It consists of four items that evaluate psychomotor function, attention, working memory, and learning and memory. CBB is used in more than 55 countries around the world, and also adopted in research through industry-government-academia collaboration in Japan and overseas. CBB is capable to detect the cognitive decline group with a high probability of sensitivity(1) 80.4% and specificity(2) 84.7% in the memory score calculated based on checking items to evaluate working memory and learning and memory.(3)

In the United States, Europe, Australia, and New Zealand, CBB has been developed by Cogstate with the function of providing expert assessment feedback for healthcare professional use and has been approved as a medical device with the name "CognigramTM". It is being used by doctors and other healthcare professionals in examination and diagnosis of MCI (Mild Cognitive Impairment) and dementia.

In Japan, Eisai developed the cognitive function test as a tool (non-medical device) for self-assessment of brain performance (brain health) to create an opportunity for a re-consideration of daily lifestyle as well as greater preventive measures, and has distributed it with the name "NouKNOW" since March in 2020. "CogMate" is a multilingual overseas model of "NouKNOW".
For more information about "NouKNOW", please visit https://nouknow.jp (Japanese only).

(1) An index that indicates whether a person can be properly detected as having a problem.
(2) An index that indicates whether a person who has no problem can be properly detected as having no problem.
(3) Maruff, P., Lim, Y. Y., Darby, D., Ellis, K. A., Pietrzak, R. H., Snyder P. J., Bush, A. I., Szoeke, C., Schembri, A., Ames,
D., Masters, C. L., & the AIBL Research Group (2013). Clinical utility of the Cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Pharmacology & Toxicology, 1:30

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai

Copyright 2022 JCN Newswire . All rights reserved.

More News

View More
3 Heavily Shorted Stocks That Could Pop on Rate Cuts
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers ETSY SMR SOUN
Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
Via MarketBeat
Tickers AVGO META
PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Via MarketBeat
Tickers PEP
Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been
Via MarketBeat
Tickers DKNG
Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom
Via MarketBeat
Tickers BUD STZ
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.